Drug Trial Radar · NCT03740529
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
803
Actual
Start
Mar 15, 2019
Primary completion
Jan 27, 2025
Study completion Dec 23, 2025
Sponsor
- Lead sponsor
- Loxo Oncology, Inc.Eli Lilly (LLY)
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Nov 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
Conditions
- Chronic Lymphocytic Leukemia
- Waldenstrom Macroglobulinemia
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- B-cell Lymphoma
- Small Lymphocytic Lymphoma
Interventions
PirtobrutinibDrug
Oral
VenetoclaxDrug
Oral
RituximabDrug
IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD)Time frame: Up to 24 Months
- Recommended dose for further studyTime frame: Up to 24 Months
- To assess the preliminary anti-tumor activity of pirtobrutinib based on ORR as assessed by an Independent Review Committee (IRC).Time frame: Up to 24 months
- To evaluate the safety of pirtobrutinib in combination with venetoclax (Arm A) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0Time frame: Up to 24 Months
- To evaluate the safety of pirtobrutinib in combination with venetoclax and rituximab (Arm B) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0Time frame: Up to 24 Months
Locations
56 sites in 10 countries. Site status is shown where the registry gives one.
Mayo Clinic of Scottsdale
Scottsdale, Arizona
Scripps Coastal Medical Center
San Diego, California
University of California San Francisco, Medical Center at Paranassus
San Francisco, California
Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut
Mayo Clinic-Jacksonville
Jacksonville, Florida
Florida Cancer Specialists ORLANDO/DDU
Lake Mary, Florida
Sylvester Comprehensive Cancer Center
Miami, Florida
Florida Cancer Specialists
Sarasota, Florida
Emory Clinic
Atlanta, Georgia
Northwestern University
Chicago, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Dana-Farber Cancer Institute
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
University of Nebraska Medical Center
Omaha, Nebraska
Roswell Park Cancer Institute
Buffalo, New York
Northwell Health
New Hyde Park, New York
Columbia University Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Durham VA Medical Center
Durham, North Carolina
Duke University Medical Center
Durham, North Carolina
Cleveland Clinic Foundation
Cleveland, Ohio
Ohio State University Hospital
Columbus, Ohio
University of Pennsylvania Hospital
Philadelphia, Pennsylvania
Sarah Cannon Research Institute SCRI
Nashville, Tennessee
Mary Crowley Cancer Research Center
Dallas, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
Utah Cancer Specialists
Salt Lake City, Utah
Swedish Medical Center
Seattle, Washington
Seattle Cancer Care Alliance
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Flinders Medical Centre
Bedford Park, South Australia, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu
Nantes, France
IRCCS - AOU di Bologna
Bologna, Italy
IRCCS Ospedale San Raffaele
Milan, Italy
National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan
Kyoto Furitsu Medical University Hospital
Kyoto, Japan
Okayama University Hospital
Okayama, Japan
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.